| 52 Week Rng | - |
| Market Cap | - |
| Avg Volume | - |
| 1M Volatility | - |
| Short Ratio | - |
| P/E Ratio (TTM) | - |
| P/E Ratio (Fwd) | - |
| P/B Ratio | - |
| Div & Yield | - |
Täffä_Spagetti_Analytics • Aalto Investment Management Game (Fall 2020) • Nov 2020
Gilead Sciences Short position Constructing our initial portfolio The firm has recently reached its 52-week low so according to our 52-week high/low momentum investment strategy, we expect the firm to be decreasing in value further in the near future due to the negative momentum it is experiencing. (Aiming for a leverage ratio of 1.8)
tr3samigos • Aalto Investment Management Game (Fall 2020) • Nov 2020
Short position with this company is suitable with the investment strategy of the fund as it has been in bottom 20 performers among S&P500 companies during the past six months. This transaction facilitates reaching an investment portfolio with equal weights between holdings.
Aurinkoiset • Aalto Investment Management Game (Fall 2020) • Nov 2020
Passive strategy. Gilead's drug remdesivir was one of the early treatment options for Covid-19. Company has good pipeline.
apanzera94 • Stockfuse Continuum (US) • Oct 2020
Automatic trade executed by Stockfuse to ensure margin compliance.
cmax • Stockfuse Continuum (US) • Oct 2020
Automatic trade executed by Stockfuse to ensure margin compliance.
roganad4608 • Stockfuse Continuum (US) • Oct 2020
Low price and potential to boom soon